Score Overview
Explore the 2021 public Archive ranking →
Where Regeneron Pharmaceuticals Inc has ranked, year by year
Showing 20 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- REGN
2012: 93.0% · 2021: 21.3% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-28 | $ 752.25 | — |
1 Year2025-09-26 | $ 561.02 | 34.09% |
5 Years2021-09-28 | $ 599.34 | 25.51% |
10 Years2016-09-28 | $ 415.18 | 81.19% |
20 Years2006-09-28 | $ 15.91 | 47x |
30 Years1996-09-27 | $ 19.19 | 39x |
All Time1991-04-02 | $ 20.93 | 35x |
| Period | Last Price2026-09-28 | 1 Year2025-09-26 | 5 Years2021-09-28 | 10 Years2016-09-28 | 20 Years2006-09-28 | 30 Years1996-09-27 | All Time1991-04-02 |
|---|---|---|---|---|---|---|---|
| Price | $ 752.25 | $ 561.02 | $ 599.34 | $ 415.18 | $ 15.91 | $ 19.19 | $ 20.93 |
| Return | — | 34.09% | 25.51% | 81.19% | 47x | 39x | 35x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 15.53B | $ 4.32B | |
| 2025 | $ 14.34B | $ 4.50B | $ 8.60B |
| 2024 | $ 14.20B | $ 4.41B | $ 9.01B |
| 2023 | $ 13.11B | $ 3.95B | $ 10.84B |
| 2022 | $ 12.17B | $ 4.33B | $ 7.74B |
| 2021 | $ 16.07B | $ 8.07B | $ 5.69B |
| 2020 | $ 8.49B | $ 3.51B | $ 6.72B |
| 2019 | $ 7.86B | $ 2.11B | $ 3.21B |
| 2018 | $ 6.71B | $ 2.44B | $ 4.56B |
| 2017 | $ 5.87B | $ 1.19B | $ 2.89B |
| 2016 | $ 4.86B | $ 895M | $ 1.03B |
| 2015 | $ 4.10B | $ 636M | $ 1.67B |
| 2014 | $ 2.81B | $ 348M | $ 1.36B |
| 2013 | $ 2.10B | $ 424M | $ 693M |
| 2012 | $ 1.37B | $ 750M | $ 308M |
| 2011 | $ 445M | -$ 221M | $ 526M |
| 2010 | $ 459M | -$ 104M | $ 249M |
| 2009 | $ 379M | -$ 67M | $ 341M |
| 2008 | $ 238M | -$ 82M | $ 474M |
| 2007 | $ 125M | -$ 105M | $ 766M |
| 2006 | $ 63M | -$ 102M | $ 459M |
| 2005 | $ 66M | -$ 95M | $ 298M |
| 2004 | $ 174M | $ 41M | $ 295M |
| 2003 | $ 57M | -$ 107M | $ 293M |
| 2002 | $ 21M | -$ 124M | $ 264M |
| 2001 | $ 21M | -$ 76M | $ 385M |
| 2000 | $ 59M | -$ 23M | $ 117M |
| 1999 | $ 34M | -$ 23M | $ 66M |
| 1998 | $ 38M | -$ 8M | $ 19M |
| 1997 | $ 33M | -$ 11M | $ 28M |
| 1996 | $ 24M | -$ 32M | $ 34M |
| 1995 | $ 27M | -$ 23M | $ 32M |
| 1994 | $ 23M | -$ 30M | $ 23M |
| 1993 | $ 10M | -$ 39M | $ 12M |
| 1992 | $ 11M | -$ 19M | $ 16M |
| IPO1991 | $ 7M | -$ 4M | $ 26M |
Regeneron Pharmaceuticals Inc fundamental performance
Between 2005 and 2025, revenue grew from $ 66M to $ 14.34B and net income went from -$ 95M to $ 4.50B. Revenue increased in 18 of those 20 years; net income in 11.
Between 1995 and 2025, revenue grew from $ 27M to $ 14.34B and net income went from -$ 23M to $ 4.50B. Revenue increased in 24 of those 30 years; net income in 15.
Regeneron Pharmaceuticals Inc currently holds a 20-year HDB Score of 7.8 out of 10. How the HDB Score is calculated.
Membership
Continue REGN’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,816 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
